Upjohn's Halcion
Executive Summary
Psychopharmacologic Drugs Advisory Committee will review "new information bearing on the safety and effectiveness" of the benzodiazepine sleep-aid at its May 8 meeting. Upjohn has said it expected such a review ("The Pink Sheet" April 20, p. 19). The meeting will begin at 8:30 a.m. in Conference Rooms D & E of FDA's Parklawn Building.